Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

M. G. Kris, Richard J. Gralla, D. P. Kelsen, E. S. Casper, M. T. Burke, J. J. Fiore, I. R. Cibas, R. T. Heelan

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.

Original languageEnglish (US)
Pages (from-to)377-379
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume8
Issue number5
StatePublished - 1985
Externally publishedYes

Fingerprint

Idarubicin
Non-Small Cell Lung Carcinoma
Daunorubicin
Leukopenia
Appointments and Schedules
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kris, M. G., Gralla, R. J., Kelsen, D. P., Casper, E. S., Burke, M. T., Fiore, J. J., ... Heelan, R. T. (1985). Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 8(5), 377-379.

Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer. / Kris, M. G.; Gralla, Richard J.; Kelsen, D. P.; Casper, E. S.; Burke, M. T.; Fiore, J. J.; Cibas, I. R.; Heelan, R. T.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 8, No. 5, 1985, p. 377-379.

Research output: Contribution to journalArticle

Kris, MG, Gralla, RJ, Kelsen, DP, Casper, ES, Burke, MT, Fiore, JJ, Cibas, IR & Heelan, RT 1985, 'Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 8, no. 5, pp. 377-379.
Kris, M. G. ; Gralla, Richard J. ; Kelsen, D. P. ; Casper, E. S. ; Burke, M. T. ; Fiore, J. J. ; Cibas, I. R. ; Heelan, R. T. / Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1985 ; Vol. 8, No. 5. pp. 377-379.
@article{f58f35d92bbc4eeca22170ea226fdb64,
title = "Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer",
abstract = "4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3{\%} in 30 patients, the predicted true response rate is ≤16{\%} (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.",
author = "Kris, {M. G.} and Gralla, {Richard J.} and Kelsen, {D. P.} and Casper, {E. S.} and Burke, {M. T.} and Fiore, {J. J.} and Cibas, {I. R.} and Heelan, {R. T.}",
year = "1985",
language = "English (US)",
volume = "8",
pages = "377--379",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer

AU - Kris, M. G.

AU - Gralla, Richard J.

AU - Kelsen, D. P.

AU - Casper, E. S.

AU - Burke, M. T.

AU - Fiore, J. J.

AU - Cibas, I. R.

AU - Heelan, R. T.

PY - 1985

Y1 - 1985

N2 - 4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.

AB - 4-Demethoxydaunorubicin (4-DMDR) is an orally active analog of daunorubicin that in preclincial testing has demonstrated greater antitumor activity and less cardiotoxicity than its parent compound. Thirty-two patients with metastatic non-small cell lung cancer received 4-DMDR at a dose of 40-50 mg/m2 orally every 21 days. Thirteen patients had received no prior chemotherapy. Among the 30 adequately treated patients, one major response lasting 5.2 months was observed. Leukopenia 10-14 days after treatment was the most commonly observed toxicity. With an overall observed major response rate of 3.3% in 30 patients, the predicted true response rate is ≤16% (p = 0.05). At the dose and schedule studied in this group of patients with non-small cell lung cancer, 4-DMDR had only marginal activity.

UR - http://www.scopus.com/inward/record.url?scp=0022358221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022358221&partnerID=8YFLogxK

M3 - Article

C2 - 3864366

AN - SCOPUS:0022358221

VL - 8

SP - 377

EP - 379

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -